Lv4
418 积分 2024-01-04 加入
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
1个月前
已完结
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
2个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
2个月前
已完结
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials
2个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
2个月前
已完结
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets
3个月前
已关闭
Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials
3个月前
已完结
KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
3个月前
已完结
Systemic Treatment for Unresectable Hepatocellular Carcinoma: A Surgeon’s Perspective
3个月前
已关闭
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma
3个月前
已完结
皖公网安备34019202002308
